Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising disease burden of DMD
3.2.1.2 Increased awareness and diagnosis of DMD
3.2.1.3 Growing research funding and activities
3.2.1.4 Advancements in genetic research
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Patent analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Exon skipping drugs
5.3 Corticosteroids
5.4 Gene therapy
5.5 Other drug types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectable
Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 The Netherlands
7.3.7 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Rest of Latin America
7.6 Middle East and Africa
7.6.1 Saudi Arabia
7.6.2 South Africa
7.6.3 UAE
7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Aurobindo Pharma
8.2 Capricor Therapeutics, Inc.
8.3 Catalyst Pharmaceuticals Inc
8.4 EspeRare Foundation
8.5 FibroGen, Inc.
8.6 Italfarmaco S.p.A
8.7 NS Pharma
8.8 PTC Therapeutics, Inc.
8.9 Santhera Pharmaceuticals
8.10 Sarepta Therapeutics, Inc.
8.11 Solid Biosciences Inc.
